Paper26311728
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Garcia-Murillas I and 14 others. Sci Transl Med, 2015. Cited by 994 papers, by iCite.
Cite this record
ConductScience Library. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Papers, record 26311728. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26311728
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| DNA, Neoplasm | Major topic |
| Mutation | Major topic |
| Female | |
| High-Throughput Nucleotide Sequencing | |
| Humans | |
| Neoplasm, Residual | |
| Precision Medicine | |
| Recurrence |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 16642 | Cancer Research UK | United Kingdom | PubMed | |
| C30746/A16642 | Cancer Research UK | United Kingdom | PubMed |
Source PubMed
Trials11
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02797652 | Clinical Application of CTDNA in Operable Breast Cancer Patients | Background | ClinicalTrials.gov | |
| NCT03312374 | ctDNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal Cancer | Results | ClinicalTrials.gov | |
| NCT04228614 | Evaluation of Somatic Mutation Spectrum as Biomarker for Survival Outcome in Chinese CRC | Background | ClinicalTrials.gov | |
| NCT04985266 | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | Background | ClinicalTrials.gov | |
| NCT05058183 | Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer | Background | ClinicalTrials.gov | |
| NCT05079074 | Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer | Background | ClinicalTrials.gov | |
| NCT05131243 | the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer | Background | ClinicalTrials.gov | |
| NCT05167604 | Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC | Results | ClinicalTrials.gov | |
| NCT05227261 | Early Detection of Five Common Cancers Using the ctDNA Analysing Test | Background | ClinicalTrials.gov | |
| NCT05408897 | Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD | Results | ClinicalTrials.gov | |
| NCT06613516 | Effect of Capivasertib on ctDNA in ER Positive Breast Cancer | Background | ClinicalTrials.gov |
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 26311727 | Does molecular monitoring matter in early-stage breast cancer? | https://conductscience.org/library/papers/26311727 | PubMed |
| Comment in | 26370605 | Breast cancer: Tracking ctDNA to evaluate relapse risk. | https://conductscience.org/library/papers/26370605 | PubMed |
| Comment in | 27868036 | The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies. | https://conductscience.org/library/papers/27868036 | PubMed |
| Comment in | 28149904 | What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer. | https://conductscience.org/library/papers/28149904 | PubMed |
Cited by665
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 994 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958365 | Dynamic ctDNA-MRD in breast cancer: subtype-specific implications for perioperative decision-making, postoperative surveillance, and MRD-guided therapy. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/42958365 | PubMed |
| 42953478 | Cellular origins and evolutionary dynamics of plasma cfDNA in solid tumors: integrating germline, tumor-derived, and hematopoietic variation for MRD and treatment guidance. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42953478 | PubMed |
| 42889542 | Inflammatory breast cancer among advanced breast malignancies: diagnostic, microenvironmental, and therapeutic challenges of the rare amongst the common. | Front Oncol | 2026 | https://conductscience.org/library/papers/42889542 | PubMed |
| 42884096 | Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42884096 | PubMed |
| 42795008 | Circulating Tumor DNA-Based Molecular Residual Disease in Early-Stage Non-Small-Cell Lung Cancer: Biology, Assays, and the Path Toward MRD-Guided Care. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42795008 | PubMed |
| 42786286 | Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42786286 | PubMed |
| 42737612 | Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737612 | PubMed |
| 42728989 | Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoring. | Open Res Eur | 2026 | https://conductscience.org/library/papers/42728989 | PubMed |
| 42727049 | Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42727049 | PubMed |
| 42724567 | Assessing the utility of ctDNA as a prognostic marker in advanced ER-positive/HER2-negative breast cancer. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724567 | PubMed |
| 42713037 | Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions. | Chin J Cancer Res | 2026 | https://conductscience.org/library/papers/42713037 | PubMed |
| 42682436 | NED-oriented oncology in metastatic breast cancer: a hypothesis-driven framework integrating the tumor immune microenvironment, antibody-drug conjugates, and metastasis-directed therapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42682436 | PubMed |
| 42645355 | Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42645355 | PubMed |
| 42567927 | Charting intratumor heterogeneity from bench to bedside. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42567927 | PubMed |
| 42558411 | Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42558411 | PubMed |
| 42512406 | Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512406 | PubMed |
| 42509573 | Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience. | Genome Med | 2026 | https://conductscience.org/library/papers/42509573 | PubMed |
| 42500286 | Development and internal validation of a radiomics-clinical combined model for predicting axillary pathological complete response in clinically node-positive breast cancer patients after neoadjuvant chemotherapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42500286 | PubMed |
| 42472109 | The role of serologic biomarkers "liquid biopsy" in the fight against breast cancer: From biological foundations to clinical impact. | iScience | 2026 | https://conductscience.org/library/papers/42472109 | PubMed |
| 42455255 | Optimizing Extended Adjuvant Endocrine Therapy in Early HR+/HER2- Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD. | Adv Ther | 2026 | https://conductscience.org/library/papers/42455255 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26311728
GET https://conductscience.org/api/papers/v1/26311728/cited_by?page=2